National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

autologous dendritic cell-tumor fusion vaccine
A therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with autologous tumor cells with potential immunostimulatory and antineoplastic activities. Autologous dendritic cell-tumor fusion vaccine is generated in vitro by mixing DCs and irradiated tumor cells harvested from individual patients and treating them with polyethylene glycol (PEG) to produce DC-tumor cell fusion hybrid cells. Upon administration, autologous dendritic cell-tumor fusion vaccine may elicit antitumor humoral and cellular immune responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:autologous anti-PSMA gene-modified T-cells, autologous dendritic cell-adenovirus CCL21 vaccine, autologous dendritic cell-adenovirus p53 vaccine, autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine, autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine
Next:autologous dinitrophenyl-modified ovarian cancer vaccine, autologous EBV-CTL CD19CAR zeta, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-transformed B-lymphoblastoid cell vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov